CONMED (NYSE:CNMD) Given New $120.00 Price Target at Stifel Nicolaus

CONMED (NYSE:CNMD – Free Report) had its target price lowered by Stifel Nicolaus from $136.00 to $120.00 in a research report released on Thursday morning, Benzinga reports. The firm currently has a buy rating on the stock. A number of other equities research analysts have also recently commented on the company. Piper Sandler raised their […]

Leave a Reply

Your email address will not be published.

Previous post Ravens have one of NFL’s best defenses but aren’t satisfied: ‘We didn’t play to our standard’
Next post Global Indemnity Group (NASDAQ:GBLI) Now Covered by Analysts at